Published in J Antimicrob Chemother on September 01, 1996
Genetic characterization of highly fluoroquinolone-resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother (2001) 3.62
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother (1998) 2.59
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother (2000) 2.40
gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother (1998) 2.35
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.94
Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob Agents Chemother (2010) 1.70
Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (2000) 1.69
Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother (2001) 1.38
DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis. Antimicrob Agents Chemother (2002) 1.08
Development and validation of a diagnostic DNA microarray to detect quinolone-resistant Escherichia coli among clinical isolates. J Clin Microbiol (2004) 1.04
Genotype and phenotypes of an intestine-adapted Escherichia coli K-12 mutant selected by animal passage for superior colonization. Infect Immun (2011) 0.94
A mutation in Escherichia coli DNA gyrase conferring quinolone resistance results in sensitivity to drugs targeting eukaryotic topoisomerase II. Antimicrob Agents Chemother (2004) 0.93
Fluoroquinolone resistance mechanisms in an Escherichia coli isolate, HUE1, without quinolone resistance-determining region mutations. Front Microbiol (2013) 0.93
Staphylococcus aureus Colonization and Strain Type at Various Body Sites among Patients with a Closed Abscess and Uninfected Controls at U.S. Emergency Departments. J Clin Microbiol (2015) 0.87
DNA gyrase from the albicidin producer Xanthomonas albilineans has multiple-antibiotic-resistance and unusual enzymatic properties. Antimicrob Agents Chemother (2008) 0.84
Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model. Eur J Clin Microbiol Infect Dis (2013) 0.84
The use of platensimycin and platencin to fight antibiotic resistance. Infect Drug Resist (2013) 0.82
Implementation of Whole Genome Sequencing (WGS) for Identification and Characterization of Shiga Toxin-Producing Escherichia coli (STEC) in the United States. Front Microbiol (2016) 0.79
Alarmingly High Segregation Frequencies of Quinolone Resistance Alleles within Human and Animal Microbiomes Are Not Explained by Direct Clinical Antibiotic Exposure. Genome Biol Evol (2015) 0.78
Novel Phagocytosis-Resistant Extended-Spectrum β-Lactamase-Producing Escherichia coli From Keratitis. JAMA Ophthalmol (2016) 0.75
Isolation of Escherichia coli strains with AcrAB-TolC efflux pump-associated intermediate interpretation or resistance to fluoroquinolone, chloramphenicol and aminopenicillin from dogs admitted to a university veterinary hospital. J Vet Med Sci (2014) 0.75
Plasmid-mediated quinolone resistance in pseudomonas putida isolates from imported shrimp. Appl Environ Microbiol (2010) 0.75
Triclosan targets lipid synthesis. Nature (1998) 4.70
Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A (1976) 3.58
Deletions of chromosomal regions coding for fimbriae and hemolysins occur in vitro and in vivo in various extraintestinal Escherichia coli isolates. Microb Pathog (1990) 3.18
A large plasmid from Halobacterium halobium carrying genetic information for gas vacuole formation. Plasmid (1979) 2.79
Aggregation substance of Enterococcus faecalis mediates adhesion to cultured renal tubular cells. Infect Immun (1992) 2.69
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli. Antimicrob Agents Chemother (1998) 2.59
Detection of legionellae in hospital water samples by quantitative real-time LightCycler PCR. Appl Environ Microbiol (2001) 2.43
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother (2000) 2.40
Prospective, randomised, double blind trial of prophylaxis with single dose of co-amoxiclav before percutaneous endoscopic gastrostomy. BMJ (1999) 2.28
Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol Lett (1998) 2.24
Ochrobactrum anthropi bacteremia: report of four cases and short review. Infection (1994) 2.13
Structure and structure formation of viroids. J Mol Biol (1979) 2.03
Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J (2008) 1.97
Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants Selected with a fluoroquinolone. Antimicrob Agents Chemother (2001) 1.93
Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis (2009) 1.91
Pulsed field electrophoresis of genomic restriction fragments for the detection of nosocomial Legionella pneumophila in hospital water supplies. J Clin Microbiol (1991) 1.89
Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis (2005) 1.83
Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother (2000) 1.69
Trends in antibiotic use at a university hospital: defined or prescribed daily doses? Patient days or admissions as denominator? Infection (2006) 1.66
CRB-65 predicts death from community-acquired pneumonia. J Intern Med (2006) 1.61
Infection of Acanthamoeba castellanii by Chlamydia pneumoniae. Appl Environ Microbiol (1997) 1.55
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J (2009) 1.54
Aggregation substance promotes adherence, phagocytosis, and intracellular survival of Enterococcus faecalis within human macrophages and suppresses respiratory burst. Infect Immun (2000) 1.53
Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol (1994) 1.51
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother (1994) 1.49
Structural and biological properties of mycoplasmavirus MVL3: an unusual virus-procaryote interaction. J Virol (1979) 1.48
Staphylococcus saprophyticus urease: characterization and contribution to uropathogenicity in unobstructed urinary tract infection of rats. Infect Immun (1989) 1.47
Association of organic solvent tolerance and fluoroquinolone resistance in clinical isolates of Escherichia coli. J Antimicrob Chemother (1998) 1.47
Cloning and genetic characterization of the flagellum subunit gene (flaA) of Legionella pneumophila serogroup 1. Infect Immun (1995) 1.47
Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47
[New therapeutic strategies for community acquired pneumonia]. Internist (Berl) (2005) 1.43
Contribution of cloned virulence factors from uropathogenic Escherichia coli strains to nephropathogenicity in an experimental rat pyelonephritis model. Infect Immun (1986) 1.43
Cloning and expression of Staphylococcus saprophyticus urease gene sequences in Staphylococcus carnosus and contribution of the enzyme to virulence. Infect Immun (1989) 1.43
Genome analysis of Legionella ssp. by orthogonal field alternation gel electrophoresis (OFAGE). FEMS Microbiol Lett (1990) 1.39
The lipopolysaccharide of Legionella pneumophila serogroup 1 (strain Philadelphia 1): chemical structure and biological significance. Prog Clin Biol Res (1995) 1.37
Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J (2007) 1.34
An unusual symmetric recombinant between adenovirus type 12 DNA and human cell DNA. Proc Natl Acad Sci U S A (1981) 1.33
Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations. Eur J Clin Microbiol Infect Dis (2007) 1.31
Overexpresssion of a Legionella pneumophila homologue of the E. coli regulator csrA affects cell size, flagellation, and pigmentation. Int J Med Microbiol (2001) 1.29
Properties of Escherichia coli strains of serotype O6. Infection (1996) 1.26
Reciprocal exchange of minor components of type 1 and F1C fimbriae results in hybrid organelles with changed receptor specificities. J Bacteriol (1994) 1.23
Temperature-dependent expression of flagella in Legionella. J Gen Microbiol (1991) 1.22
Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia. Br J Haematol (2000) 1.20
Characterization of the beta-lactamases of six species of Legionella. J Bacteriol (1982) 1.20
Aggregation substance increases adherence and internalization, but not translocation, of Enterococcus faecalis through different intestinal epithelial cells in vitro. Infect Immun (2000) 1.19
Renal tolerance and pharmacokinetics of vancomycin in rats. J Antimicrob Chemother (1984) 1.17
O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Clin Diagn Lab Immunol (1997) 1.17
Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect Immun (1996) 1.17
Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother (2006) 1.16
Hemagglutinating and adherence properties of Staphylococcus saprophyticus: epidemiology and virulence in experimental urinary tract infection of rats. FEMS Microbiol Immunol (1988) 1.15
The structure of the O-specific chain of Legionella pneumophila serogroup 1 lipopolysaccharide. Eur J Biochem (1994) 1.14
Molecular epidemiology of fluoroquinolone-resistant Escherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob Agents Chemother (1996) 1.12
CAPNETZ-community-acquired pneumonia competence network. Infection (2004) 1.11
[SARS--Severe Acute Respiratory syndrome]. Pneumologie (2003) 1.09
Viroid replication: equilibrium association constant and comparative activity measurements for the viroid-polymerase interaction. Nucleic Acids Res (1984) 1.08
An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection (1998) 1.07
De novo synthesis of Legionella pneumophila antigens during intracellular growth in phagocytic cells. Infect Immun (1996) 1.06
Bacterial colonization and endotoxin contamination of intravenous infusion fluids. J Hosp Infect (1997) 1.06
Restriction and modification in B. subtilis. The biochemical basis of modification against endo R. Bsu R restriction. Mol Gen Genet (1975) 1.05
Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection (1999) 1.04
Cloning, genetic analysis, and nucleotide sequence of a determinant coding for a 19-kilodalton peptidoglycan-associated protein (Ppl) of Legionella pneumophila. Infect Immun (1991) 1.04
Differential expression of interleukin-6, intracellular adhesion molecule 1, and major histocompatibility complex class II molecules in renal carcinoma cells stimulated with S fimbriae of uropathogenic Escherichia coli. Infect Immun (1993) 1.04
Diagnostic value of procalcitonin serum levels in neutropenic patients with fever: comparison with interleukin-8. Scand J Infect Dis (1999) 1.03
Structure of viroid replicative intermediates: physico-chemical studies on SP6 transcripts of cloned oligomeric potato spindle tuber viroid. Nucleic Acids Res (1986) 1.01
Studies on bacteriophage T7 DNA synthesis in vitro. II. Reconstitution of the T7 replication system using purified proteins. Mol Gen Genet (1975) 1.01
Development and validation of potential structure indicators for evaluating antimicrobial stewardship programmes in European hospitals. Eur J Clin Microbiol Infect Dis (2013) 1.00
Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats. J Antimicrob Chemother (1990) 0.99
Diagnosis of ornithosis by cell culture and polymerase chain reaction in a patient with chronic pneumonia. Clin Infect Dis (1995) 0.99
Antibiotic use in Germany and European comparison. Dtsch Med Wochenschr (2004) 0.99
Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Infect Immun (1997) 0.99
Mycetoma due to Exophiala jeanselmei and Mycobacterium chelonae in a 73-year-old man with idiopathic CD4+ T lymphocytopenia. Mycoses (1996) 0.99
Use of a receiver operating characteristic in the evaluation of two commercial enzyme immunoassays for detection of Helicobacter pylori infection. Eur J Clin Microbiol Infect Dis (1994) 0.98
[S3-guideline on ambulant acquired pneumonia and deep airway infections]. Pneumologie (2005) 0.97
Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother (1998) 0.97
Characterization of coagulase-negative staphylococci causing nosocomial infections in preterm infants. Eur J Clin Microbiol Infect Dis (1995) 0.96
Comparison of defined versus recommended versus prescribed daily doses for measuring hospital antibiotic consumption. Infection (2009) 0.96
Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol (1998) 0.96
Aggregation substance-mediated adherence of Enterococcus faecalis to immobilized extracellular matrix proteins. Microb Pathog (2001) 0.95
Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect (2006) 0.95
Identification and characterization of a surface-associated protein (Ssp) of Staphylococcus saprophyticus. Infect Immun (1992) 0.94
Survival of Chlamydia pneumoniae-infected Mono Mac 6 cells is dependent on NF-kappaB binding activity. Infect Immun (2001) 0.94
Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis (2005) 0.93
Changes in Escherichia coli resistance patterns during and after antibiotic therapy: a longitudinal study among outpatients in Germany. Clin Microbiol Infect (2007) 0.93
Evaluation of a competitive ELISA method for the determination of Klebsiella O antigens. J Med Microbiol (1996) 0.93
A fatal infection with Alternaria alternata and Aspergillus terreus in a child with agranulocytosis of unknown origin. Mycoses (1995) 0.93